Type of information: Private placement
Company: PTC Therapeutics (USA - NJ)
Funding type: private placement
- • On January 23, 2019, PTC Therapeutics announced the pricing of a public offering of 6,720,000 shares of its common stock at a public offering price of $30.20 per share, before underwriting discounts. All of the shares in the offering are to be sold by PTC. In addition, PTC has granted the underwriter an option for a period of 30 days to purchase up to an additional 1,008,000 shares of common stock at the public offering price, less the underwriting discount. RBC Capital Markets is acting as the sole book-running manager for the offering. PTC expects to close the offering on or about January 25, 2019, subject to satisfaction of customary closing conditions.
Therapeutic area: Rare diseases - Genetic diseases